Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Johnson and Johnson
McKinsey
Harvard Business School
Colorcon

Last Updated: December 11, 2019

DrugPatentWatch Database Preview

Patent: 6,063,566

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 6,063,566
Title: Catalytic RNA molecules
Abstract:The present invention discloses nucleic acid enzymes capable of cleaving nucleic acid molecules, including single-stranded DNA, in a site-specific manner under physiologic conditions, as well as compositions including same. The present invention also discloses methods of making and using the disclosed enzymes and compositions. The present invention further discloses nucleic acid enzymes or catalytic (enzymatic) RNA molecules that are capable of cleaving a variety of bonds, including phosphodiester bonds and amide bonds, in a variety of substrates. Thus, various disclosed enzymatic RNA molecules are capable of functioning as nucleases, amidases, and/or peptidases. The present invention also relates to compositions containing the disclosed catalytic RNA molecules and to methods of making, selecting, and using such enzymes and compositions.
Inventor(s): Joyce; Gerald F. (Encinitas, CA)
Assignee: The Scripps Research Institute (CA)
Application Number:08/682,423
Patent Claims:see list of patent claims

Details for Patent 6,063,566

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial The Scripps Research Institute (CA) 2014-05-13 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial The Scripps Research Institute (CA) 2014-05-13 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial The Scripps Research Institute (CA) 2014-05-13 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 6,063,566

Country Patent Number Publication Date
World Intellectual Property Organization (WIPO) 9531551 Nov 23, 1995
World Intellectual Property Organization (WIPO) 9802583 Jan 22, 1998
United States of America 5580967 Dec 03, 1996
United States of America 5595873 Jan 21, 1997
Japan 2000515013 Nov 14, 2000
Japan H10500021 Jan 06, 1998
European Patent Office 0758386 Feb 19, 1997
>Country >Patent Number >Publication Date

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Mallinckrodt
AstraZeneca
Dow
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.